Causes and General-specialty Prevention Strategies for Drug-induced Renal Injury in the Elderly

doi:10.12114/j.issn.1007-9572.2021.00.115

Abstract

Abstract: Drug-induced kidney injury（DKI）is a drug-induced kidney disease caused by adverse drug events or reactions，which may result in acute or chronic renal failure，seriously reducing the patients' quality of life，and increasing the economic burden on families and society. So the prevention of DKI has important clinical and social significance. The elderly is a high-risk group of DKI，among whom the incidence of DKI is about 10% to 65%.Therefore，identifying the causes of DKI，studying the special clinical medication characteristics，and strengthening medication education and management in the elderly are extremely important to promote medication safety and prevent DKI in this group. This review discusses the pathophysiological mechanism，risk factors，causes and general-specialty prevention strategies for DKI in the elderly.

Key words: Drug-induced kidney injury, Aged, Adverse drug reactions, Medication safety, Prevention strategies

摘要： 药源性肾损害是由药物不良事件（ADE）和药物不良反应（ADR）所致的药源性肾脏病，可导致急、慢性肾功能衰竭，严重降低患者生活质量，增加社会家庭经济负担，因而预防其发生具有重要的临床及社会意义。老年人是药源性肾损害的高危人群，老年人药源性急性肾损伤发生率为10%~65%。因此，明确老年人药源性肾损害的原因，研究老年人特殊的临床用药特点，加强老年人用药知识的教育和管理，对促进老年人用药安全、预防药源性肾损害极为重要。本文将就药源性肾损害的病理生理机制、危险因素、老年人发生药源性肾损害的原因及全-专联合预防策略展开讨论。

关键词: 药源性肾损害, 老年人, 药物不良反应, 用药安全, 预防策略

WEI Shan,LIU Yingli. Causes and General-specialty Prevention Strategies for Drug-induced Renal Injury in the Elderly　[J]. Chinese General Practice, 2021, 24(17): 2140-2147. DOI: 10.12114/j.issn.1007-9572.2021.00.115.
魏珊,刘英莉. 老年人药源性肾损害的原因及全-专联合预防策略的探讨[J]. 中国全科医学, 2021, 24(17): 2140-2147. DOI: 10.12114/j.issn.1007-9572.2021.00.115.

References

［1］United Nations，Department of Economic and Social Affairs，Population Division （2019World Population Prospects 2019：Highlights）．［M］．UN，New York，2019：3-11.
［2］国家统计局.中华人民共和国2019年国民经济和社会发展统计公报［J］．中国统计，2020，（3）：8-22.
National Bureau of Statistics.Statistical Bulletin of the People's Republic of China on the 2019 National Economic and Social Development［J］．China Statistics，2020，（3）：8-22.
［3］BARNETT K，MERCER S W，NORBURY M，et al．Epidemiology of multimorbidity and implications for health care，research，and medical education：a cross-sectional study［J］．Lancet，2012，380（9836）：37-43．DOI：10.1016/S0140-6736（12）
60240-2.
［4］WASTESSON J W，MORIN L，TAN E C K，et al．An update on the clinical consequences of polypharmacy in older adults：a narrative review［J］．Expert Opin Drug Saf，2018，17（12）：1185-1196．DOI：10.1080/14740338.2018.1546841.
［5］O'SULLIVAN E D，HUGHES J，FERENBACH D A.Renal aging：causes and consequences［J］．J Am Soc Nephrol，2017，28（2）：407-420．DOI：10.1681/ASN.2015121308.
［6］KLOTZ U.Pharmacokinetics and drug metabolism in the elderly［J］．Drug Metab Rev，2009，41（2）：67-76．
［7］AWDISHU L，MEHTA R L.The 6R's of drug induced nephrotoxicity［J］．BMC Nephrol，2017，18（1）：124．DOI：10.1186/s12882-017-0536-3.
［8］MEHTA R L，AWDISHU L，DAVENPORT A，et al．Phenotype standardization for drug-induced kidney disease［J］．Kidney Int，2015，88（2）：226-234．DOI：10.1038/ki.2015.115.
［9］HUANG L，XUE C，KUAI J，et al．Clinical characteristics and outcomes of community-acquired versus hospital-acquired acute kidney injury：a meta-analysis［J］．Kidney Blood Press Res，2019，44（5）：879-896．DOI：10.1159/000502546.
［10］HIMMELFARB J，IKIZLER T A.Acute kidney injury：changing lexicography，definitions，and epidemiology［J］．Kidney Int，2007，71（10）：971-976．DOI：10.1038/sj.ki.5002224.
［11］JHA V，MALHOTRA H S，SAKHUJA V，et al．Spectrum of hospital-acquired acute renal failure in the developing countries—Chandigarh study［J］．Q J Med，1992，83（303）：497-505.
［12］MAHAJAN S，TIWARI S，BHOWMIK D，et al．Factors affecting the outcome of acute renal failure among the elderly population in India：a hospital based study［J］．Int Urol Nephrol，2006，38（2）：391-396．DOI：10.1007/s11255-006-0053-y.
［13］KOHLI H S，BHAT A，ARAVINDAN A N，et al．Predictors of mortality in elderly patients with acute renal failure in a developing country［J］．Int Urol Nephrol，2007，39（1）：339-344．
［14］KOHLI H S，BHASKARAN M C，MUTHUKUMAR T，et al．Treatment-related acute renal failure in the elderly：a hospital-based prospective study［J］．Nephrol Dial Transplant，2000，15（2）：212-217．DOI：10.1093/ndt/15.2.212.
［15］BARALDI A，BALLESTRI M，RAPANÀ R，et al．Acute renal failure of medical type in an elderly population［J］．Nephrol Dial Transplant，1998，13（Suppl 7）：25-29．DOI：10.1093/ndt/13.suppl_7.25.
［16］NASH K，HAFEEZ A，HOU S.Hospital-acquired renal insufficiency［J］．Am J Kidney Dis，2002，39（5）：930-936．DOI：10.1053/ajkd.2002.32766.
［17］LI Q，ZHAO M，DU J，et al．Outcomes of renal function in elderly patients with acute kidney injury［J］．Clin Interv Aging，2017，12：153-160．DOI：10.2147/CIA.S121823.
［18］SESSO R，ROQUE A，VICIOSO B，et al．Prognosis of ARF in hospitalized elderly patients［J］．Am J Kidney Dis，2004，44（3）：410-419.
［19］HSU C N，LEE C T，SU C H，et al．Incidence，outcomes，and risk factors of community-acquired and hospital-acquired acute kidney injury：a retrospective cohort study［J］．Medicine （Baltimore），2016，95（19）：e3674．DOI：10.1097/MD.0000000000003674.
［20］MARKOWITZ G S，BOMBACK A S，PERAZELLA M A.Drug-induced glomerular disease：direct cellular injury［J］．Clin J Am Soc Nephrol，2015，10（7）：1291-1299．DOI：10.2215/CJN.00860115.
［21］INUI K I，MASUDA S，SAITO H.Cellular and molecular aspects of drug transport in the kidney［J］．Kidney Int，2000，58（3）：944-958．DOI：10.1046/j.1523-1755.2000.00251.x.
［22］TIONG H Y，HUANG P，XIONG S，et al．Drug-induced nephrotoxicity：clinical impact and preclinical in vitro models［J］．Mol Pharm，2014，11（7）：1933-1948．DOI：10.1021/mp400720w.
［23］HOGAN J J，MARKOWITZ G S，RADHAKRISHNAN J.Drug-induced glomerular disease：immune-mediated injury［J］．Clin J Am Soc Nephrol，2015，10（7）：1300-1310．DOI：10.2215/CJN.01910215.
［24］DAUDON M，FROCHOT V，BAZIN D，et al．Drug-induced kidney stones and crystalline nephropathy：pathophysiology，prevention and treatment［J］．Drugs，2018，78（2）：163-201．DOI：10.1007/s40265-017-0853-7.
［25］Al-NOURI Z L，REESE J A，TERRELL D R，et al．Drug-induced thrombotic microangiopathy：a systematic review of published reports［J］．Blood，2015，125（4）：616-618．
［26］PERAZELLA M A.Pharmacology behind common drug nephrotoxicities［J］．Clin J Am Soc Nephrol，2018，13（12）：1897-1908．DOI：10.2215/CJN.00150118.
［27］陈伟，刘华锋.抗菌药物相关急性肾损伤的新认识［J］．临床合理用药杂志，2010，3（1）：124-126．DOI：10.15887/j.cnki.13-1389/r.2010.01.099
CHEN W，LIU H F.New understanding of acute kidney injury related to antibiotics［J］．Chinese Journal of Clinical Rational Drug Use，2010，3（1）：124-126．DOI：10.15887/j.cnki.13-1389/r.2010.01.099.
［28］HUO X，LIU K.Renal organic anion transporters in drug-drug interactions and diseases［J］．Eur J Pharm Sci，2018，112：8-19．DOI：10.1016/j.ejps.2017.11.001.
［29］DENIC A，GLASSOCK R J，RULE A D.Structural and functional changes with the aging kidney［J］．Adv Chronic Kidney Dis，2016，23（1）：19-28．DOI：10.1053/j.ackd.2015.08.004.
［30］LINDEMAN R D，TOBIN J，SHOCK N W.Longitudinal studies on the rate of decline in renal function with age［J］．J Am Geriatr Soc，1985，33（4）：278-285．DOI：10.1111/j.1532-5415.1985.tb07117.x.
［31］IMAI E，HORIO M，YAMAGATA K，et al．Slower decline of glomerular filtration rate in the Japanese general population：a longitudinal 10-year follow-up study［J］．Hypertens Res，2008，31（3）：433-441．DOI：10.1291/hypres.
［32］HOMMOS M S，GLASSOCK R J，RULE A D.Structural and functional changes in human kidneys with healthy aging［J］．J Am Soc Nephrol，2017，28（10）：2838-2844．DOI：10.1681/ASN.2017040421.
［33］JOCHEMSEN R，NANDI K L，CORLESS D，et al．Pharmacokinetics of brotizolam in the elderly［J］．Br J Clin Pharmacol，1983，16（Suppl 2）：299S-307S．DOI：10.1111/j.1365-2125.1983.tb02304.x.
［34］SOENEN S，RAYNER C K，JONES K L，et al．The ageing gastrointestinal tract［J］．Curr Opin Clin Nutr Metab Care，2016，19（1）：12-18．DOI：10.1097/MCO.0000000000000238.
［35］ROBERTS A G，GIBBS M E.Mechanisms and the clinical relevance of complex drug-drug interactions［J］．Clin Pharmacol，2018，10：123-134．DOI：10.2147/CPAA.S146115.
［36］UPADHYA B，TAFFET G E，CHENG C P，et al．Heart failure with preserved ejection fraction in the elderly：scope of the problem［J］．J Mol Cell Cardiol，2015，83：73-87．DOI：10.1016/j.yjmcc.2015.02.025.
［37］REINDERS I，VISSER M，SCHAAP L.Body weight and body composition in old age and their relationship with frailty［J］．Curr Opin Clin Nutr Metab Care，2017，20（1）：11-15．DOI：10.1097/MCO.0000000000000332.
［38］MAKIZAKO H，SHIMADA H，DOI T，et al．Age-dependent changes in physical performance and body composition in community-dwelling Japanese older adults［J］．J Cachexia Sarcopenia Muscle，2017，8（4）：607-614．DOI：10.1002/jcsm.12197.
［39］HANRATTY C G，MCGLINCHEY P，JOHNSTON G D，et al．Differential pharmacokinetics of digoxin in elderly patients［J］．Drugs Aging，2000，17（5）：353-362．DOI：10.2165/00002512-200017050-00003.
［40］TAJIRI K，SHIMIZU Y.Liver physiology and liver diseases in the elderly［J］．World J Gastroenterol，2013，19（46）：8459-8467．DOI：10.3748/wjg.v19.i46.8459.
［41］DOAN J，ZAKRZEWSKI-JAKUBIAK H，ROY J，et al．Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy［J］．Ann Pharmacother，2013，47（3）：324-332．DOI：10.1345/aph.1R621.
［42］BURRIS J F，TORTORICI M A，MANDIC M，et al．Dosage adjustments related to young or old age and organ impairment［J］．J Clin Pharmacol，2016，56（12）：1461-1473．DOI：10.1002/jcph.816.
［43］CORSONELLO A，PEDONE C，INCALZI R A.Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions［J］．Curr Med Chem，2010，17（6）：571-584．DOI：10.2174/092986710790416326.
［44］SCONDOTTO G，POJERO F，POLLINA ADDARIO S，et al．The impact of polypharmacy and drug interactions among the elderly population in Western Sicily，Italy［J］．Aging Clin Exp Res，2018，30（1）：81-87．DOI：10.1007/s40520-017-0755-2.
［45］王烁烁，许丽雅，陈长香，等．社区老年人经济地位与医疗负担对老年人用药行为影响［J］．中国公共卫生，2020，36（10）：1429-1432．DOI：10.11847/zgggws1123929.
WANG S S，XU L Y，CHEN C X，et al．Influence of economic condition and medical burden on medication behaviors among community elderly people［J］．Chinese Journal of Public Health，2020，36（10）：1429-1432．DOI：10.11847/zgggws1123929.
［46］马翔宇，侯宁.老年人潜在不适当用药调查分析［J］．中国医院用药评价与分析，2019，19（8）：1017-1020．DOI：10.14009/j.issn.1672-2124.2019.08.036.
MA X Y，HOU N.Investigation and analysis of potential inappropriate drug application among the elderly［J］．Evaluation and Analysis of Drug-Use in Hospitals of China，2019，19（8）：1017-1020．DOI：10.14009/j.issn.1672-2124.2019.08.036.
［47］何淑莹，梁文汉，赵新生，等．Beers标准评价某基层医院门诊心血管内科老年人用药［J］．中国现代药物应用，2019，13（8）：153-155．DOI：10.14164/j.cnki.cn11-5581/r.2019.08.090.
HE S Y，LAING W H，ZHAO X S，et al．Beers standard evaluation of drugs used by the elderly in the cardiovascular department of a primary hospital［J］．Chinese Journal of Modern Drug Application，2019，13（8）：153-155．DOI：10.14164/j.cnki.cn11-5581/r.2019.08.090.
［48］高翔，黄婷，陈杰，等．老年高血压住院患者潜在不适当用药调查［J］．中国老年学杂志，2019，39（5）：1223-1226．DOI：10.3969/j.issn.1005-9202.2019.05.063.
GAO X，HUANG T，CHEN J，et al．Investigation of potential inappropriate medications in elderly hypertensive inpatients［J］．Chinese Journal of Gerontology，2019，39（5）：1223-1226．DOI：10.3969/j.issn.1005-9202.2019.05.063.
［49］CHARLESWORTH C J，SMIT E，LEE D S，et al．Polypharmacy among adults aged 65 years and older in the united states：1988—2010［J］．J Gerontol A Biol Sci Med Sci，2015，70（8）：989-995．DOI：10.1093/gerona/glv013.
［50］GUTHRIE B，MAKUBATE B，HERNANDEZ-SANTIAGO V，et al．The rising tide of polypharmacy and drug-drug interactions：population database analysis 1995—2010［J］．BMC Med，2015，13：74．DOI：10.1186/s12916-015-0322-7.
［51］BOURGEOIS F T，SHANNON M W，VALIM C，et al．Adverse drug events in the outpatient setting：an 11-year national analysis［J］．Pharmacoepidemiol Drug Saf，2010，19（9）：901-910．DOI：10.1002/pds.1984.
［52］LAZAROU J，POMERANZ B H，COREY P N.Incidence of adverse drug reactions in hospitalized patients：a meta-analysis of prospective studies［J］．JAMA，1998，279（15）：1200-1205．DOI：10.1001/jama.279.15.1200.
［53］CLASSEN D C，PESTOTNIK S L，EVANS R S，et al．Adverse drug events in hospitalized patients.Excess length of stay，extra costs，and attributable mortality［J］．JAMA，1997，277（4）：301-306.
［54］HANLON J T，SCHMADER K E，RUBY C M，et al．Suboptimal prescribing in older inpatients and outpatients［J］．J Am Geriatr Soc，2001，49（2）：200-209．DOI：10.1046/j.1532-5415.2001.49042.x.
［55］於亚洲，卢振，张丽芳，等．黄石市社区老年人用药依从性现状及影响因素研究［J］．中国药业，2019，28（3）：90-92．DOI：10.3969/j.issn.1006-4931.2019.03.029.
YU Y Z，LU Z，ZHANG L F，et al．Study on the current situation and influencing factors of medication compliance of the elderly in a community in Huangshi City［J］．China Pharmaceuticals，2019，28（3）：90-92．DOI：10.3969/j.issn.1006-4931.2019.03.029.
［56］王秋梅，闫雪莲，刘晓红，等．老年人用药依从性及其相关影响因素分析［J］．中国临床保健杂志，2018，21（2）：148-152．DOI：10.3969/J.issn.1672-6790.2018.02.002.
WANG Q M，YAN X L，LIU X H，et al．Medication adherence and the related influential factors among the elderly patients［J］．Chinese Journal of Clinical Healthcare，2018，21（2）：148-152．DOI：10.3969/J.issn.1672-6790.2018.02.002.
［57］郭志钢，王涵，吕霁航，等．老年人安全用药情况国内外对比研究［J］．长春中医药大学学报，2019，35（1）：185-187，192．DOI：10.13463/j.cnki.cczyy.2019.01.054.
GUO Z G，WANG H，LYU J H，et al．Comparison of proper usage of medicines for elderly between China and foreign countries［J］．Journal of Changchun University of Traditional Chinese Medicine，2019，35（1）：185-187，192．DOI：10.13463/j.cnki.cczyy.2019.01.054.
［58］钟运香，卢锐辉，何碧娟，等．药师应用SOAP药历对药源性肾损伤患者的药学监护［J］．中国医院用药评价与分析，2019，19（5）：622-624．DOI：10.14009/j.issn.1672-2124.2019.05.033.
ZHONG Y X，LU R H，HE B J，et al．Pharmaceutical care for patients with drug-induced renal injury by clinical pharmacists with application of SOAP medication record［J］．Evaluation and Analysis of Drug-Use in Hospitals of China，2019，19（5）：622-624．DOI：10.14009/j.issn.1672-2124.2019.05.033.

[1]	XU Jialan, YAN Hong, WEN Jun, ZHOU Zitong, WANG Siyu. Prevalence of Potentially Inappropriate Medication in Older Adults with Cancer: a Meta-analysis [J]. Chinese General Practice, 2025, 28(30): 3815-3822.
[2]	LI Ling, LI Yaping, QIAN Shixing, NIE Jing, LU Chunhua, LI Xia. Research on Influencing Factors and Risk Prediction of Cognitive Function in Community-dwelling Middle-aged and Elderly People [J]. Chinese General Practice, 2025, 28(30): 3773-3778.
[3]	YU Wenhua, LI Jianguo, DUAN Wenyan, GAO Xuyan, LI Xiaxia, ZHANG Zilong, ZHANG Li, MA Lina. Reliability and Validity of the Function Impairment Screening Tool among Community-dwelling Older Adults [J]. Chinese General Practice, 2025, 28(24): 3000-3004.
[4]	YANG Chen, CHEN Tong, ZHANG Lifang, ZHANG Hongxu, LI Pengfei, ZHANG Xuejuan. Prognostic Impact of Dapagliflozin in Elderly Breast Cancer Survivors with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes [J]. Chinese General Practice, 2025, 28(24): 3053-3058.
[5]	LI Jiaxin, LIU Zhonghui, XIE Shuo, FU Zhifang, SUN Dan, JIAO Hongmei. Trajectory in Biomarkers of Metabolic and Inflammatory States as Early Predictors of Chronic Critical Illness in Aging Patients [J]. Chinese General Practice, 2025, 28(24): 2993-2999.
[6]	ZHAO Xiaoqing, GUO Tongtong, ZHANG Xinyi, LI Linhong, ZHANG Ya, JI Lihong, DONG Zhiwei, GAO Qianqian, CAI Weiqing, ZHENG Wengui, JING Qi. Construction and Validation of a Risk Prediction Model for Cognitive Impairment in Community-dwelling Older Adults [J]. Chinese General Practice, 2025, 28(22): 2776-2783.
[7]	SHI Xiaotian, WANG Shan, YANG Huayu, YANG Yifan, LI Xu, MA Qing. Association between Body Mass Index and Mortality among Older Chinese: a Cohort Study [J]. Chinese General Practice, 2025, 28(22): 2791-2797.
[8]	LIU Meixia, YIN Jinnian, WU Mei, YANG Xing, ZHOU Quanxiang, YANG Jingyuan. Impact of Body Mass Index on the Association of Triglyceride Glucose Index with Cognitive Function: a Cross-sectional Study in Rural Older Adults in Guizhou Province [J]. Chinese General Practice, 2025, 28(22): 2806-2812.
[9]	HAO Aihua, ZENG Ziying, JIN Aiqiong, TANG Lingling, ZHENG Zique, MA Jingtai, ZHAO Jianguo, ZENG Weilin, XIAO Jianpeng, NIE Hui, YANG Ying. Analysis of Factors Influencing Avoidable Hospitalization for Elderly Hypertensive Patients [J]. Chinese General Practice, 2025, 28(19): 2370-2375.
[10]	CHEN Qiaoqiao, SU Ping, ZHAO Yingying, PANG Jinhong, SHI Jie, WANG Yaqian, LI Qiuchun, HE Ruiyan, WANG Yue, CHEN Xueyu, QIAO Junpeng, CHI Weiwei. Association between Triglyceride-Glucose Index and Incident Cardiometabolic Multimorbidity in the Elderly: a Prospective Cohort Study [J]. Chinese General Practice, 2025, 28(18): 2270-2277.
[11]	JIANG Xiaoman, XU Xinyi, DING Lingyu, GUO Yinning, MIAO Xueyi, CHEN Li, XU Qin. Clinical Characteristics and Correlation between Preoperative Frailty and Metabolic Syndrome among Older Patients with Gastric Cancer [J]. Chinese General Practice, 2025, 28(17): 2134-2141.
[12]	WANG Biqing, ZHANG Ping, YANG Hongxia, WANG Qian, JU Chunxiao, ZHAO Junnan, MEI Jun, ZHANG Ying, XU Fengqin. Meta-analysis of Prevalence and Development Trend of Mild Cognitive Impairment in Elderly Hypertensive Patients in China [J]. Chinese General Practice, 2025, 28(17): 2186-2192.
[13]	LIU Yuting, QIU Lixia, LI Yuling. Impact of Frailty on Cognitive Function in Chinese Older Adults: a Moderated Chain-mediated Effect [J]. Chinese General Practice, 2025, 28(17): 2119-2126.
[14]	SONG Xiaoling, ZHENG Li, JIN Juzhen, MAO Guangyan, SHANG Yuanhao, HU Jin, WANG Junhua, WANG Ziyun. Association between Sleep Quality and Atherosclerosis among Population Aged 40-65 Years [J]. Chinese General Practice, 2025, 28(17): 2113-2118.
[15]	HUANG Zhijie, MAI Zhihua, WANG Haoxiang, HE Yuming, DENG Qiaoyan, DAI Ranran, ZHOU Zhiheng. Multimorbidity of Hypertension, Diabetes, and Dyslipidemia and Influencing Factors of Family Function among the Elderly [J]. Chinese General Practice, 2025, 28(16): 2001-2010.